Medi-Stim ASA

Medistim is engaged in the developing, producing, service, leasing and distribution of medical devices. Co. develops, manufactures and brings to market the quality assessment systems VeriQ™ and VeriQ C™ for cardiac, vascular and transplant surgery. In addition, Co. is a distributor of other medical devices through its subsidiaries: Medistim Norge AS, Medistim Danmark Aps and Medistim Deutschland GmbH. The products distributed are mainly medical devices within all types of surgery.Minus income tax paidInbound VAT receivable
  • TickerMEDI
  • ISINNO0010159684
  • ExchangeOslo Bors
  • SectorHealth Care Equipment & Services
  • CountryNorway
Ole-Andreas Krohn

Medistim (Sell, TP: NOK175.00) - Q2 set to reflect Covid-19

We expect Medistim’s Q2 report (due before the open on 14 August) to reflect a reduction in activity, given limited access to clinics during the quarter with those clinics also likely to be prioritising only the most urgent surgeries due to the Covid-19 outbreak. Based on the medium- to long-term outlook, we have raised our target price to NOK175 (160). We reiterate our SELL.

Håkon Astrup ...
  • Jesper Ingildsen
  • Jørgen Lian
  • Ole Martin Westgaard
  • Ole-Andreas Krohn

Northern Lights

Medistim ASA: 1 director sold

Two Directors at Medistim ASA sold 38,415 shares at between 160.910NOK and 163.000NOK. The significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Ole-Andreas Krohn

Medistim (Sell, TP: NOK160.00) - Strong report, but headwinds next

Release of the pent-up demand for upgrades in Japan sooner than expected and less impact from Covid-19 than we feared lifted the Q1 report above our estimates. However, we still find the valuation stretched and remain cautious. The Covid-19 impact remains uncertain and we see downside risk into Q2. We have raised our target price to NOK160 (148), but reiterate our SELL on valuation.

Christoffer Wang Bjørnsen ...
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Tomi Railo

Northern Lights

Medistim ASA: 1 director sold

Two Directors at Medistim ASA sold 38,415 shares at between 160.910NOK and 163.000NOK. The significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Ole-Andreas Krohn

Medistim (Sell, TP: NOK175.00) - Q2 set to reflect Covid-19

We expect Medistim’s Q2 report (due before the open on 14 August) to reflect a reduction in activity, given limited access to clinics during the quarter with those clinics also likely to be prioritising only the most urgent surgeries due to the Covid-19 outbreak. Based on the medium- to long-term outlook, we have raised our target price to NOK175 (160). We reiterate our SELL.

Ole-Andreas Krohn

Medistim (Sell, TP: NOK160.00) - Strong report, but headwinds next

Release of the pent-up demand for upgrades in Japan sooner than expected and less impact from Covid-19 than we feared lifted the Q1 report above our estimates. However, we still find the valuation stretched and remain cautious. The Covid-19 impact remains uncertain and we see downside risk into Q2. We have raised our target price to NOK160 (148), but reiterate our SELL on valuation.

Ole-Andreas Krohn

Medistim (Sell, TP: NOK148.00) - Clients have other priorities, for now

Short- to medium-term visibility has been hampered by the Covid-19 pandemic, and we see downside potential with the valuation now looking stretched. We have therefore downgraded our recommendation to SELL (HOLD), but reiterate our NOK148 target price.

Ole-Andreas Krohn

Medistim (Hold, TP: NOK148.00) - Clients stretched on capacity

As global healthcare capacity is stretched to its limit while treating coronavirus patients, we expect clinics to postpone capex purchases until the situation normalises. Following a downward revision of platform sales, we reiterate our HOLD and have lowered our target price to NOK148 (150).

Ole-Andreas Krohn

Medistim (Hold, TP: NOK150.00) - Steady through uncertain times

Medistim (MEDI NO, Hold) - Steady through uncertain times (21 pages)

Håkon Astrup ...
  • Jesper Ingildsen
  • Jørgen Lian
  • Ole Martin Westgaard
  • Ole-Andreas Krohn

Northern Lights

Christoffer Wang Bjørnsen ...
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Tomi Railo

Northern Lights

Christer Magnergård ...
  • Håkon Astrup
  • Jimi Lehtonen
  • Joachim Gunell
  • Martin Arnell
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling

Northern Lights

Christoffer Wang Bjørnsen ...
  • Karl-Johan Bonnevier
  • Ole-Andreas Krohn
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Jon Masdal
  • Marius Knudssøn
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Patrik Ling
  • Paul Harper

Northern Lights

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch